CYP2C19 and coronary artery disorder: Central databases were searched up to 30 August 2025, for studies evaluating the use of point-of-care CYP2C19 genotyping to guide antiplatelet therapy in ACS/CAD patients undergoing PCI, comparing clinical efficacy and safety with conventional P2Y12 inhibitors.